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Under basal growth conditions, p53 function is tightly controlled by the members of MDM family, MDM2 and MDM4. The Mdm2 gene codes, in addition to the full-length p90 MDM2 , for a short protein, p76
MDM2 that lacks the p53-binding domain. Despite this property and at variance with p90
MDM2
, this protein acts positively toward p53, although the molecular mechanism remains elusive. Here, we report that p76
MDM2 antagonizes MDM4 inhibitory function. We show that p76 MDM2 possesses intrinsic ubiquitinating and degrading activity, and through these activities controls MDM4 levels. Furthermore, the presence of p76 MDM2 decreases the association of MDM4 with p53 and p90
, and antagonizes p53 degradation by the heterodimer MDM4/p90
. The p76
-mediated regulation of MDM4 occurs in the cytoplasm, under basal growth conditions. Conversely, upon DNA damage, phosphorylation of MDM4Ser403 dissociates p76 MDM2 and prevents MDM4 degradation. The overall negative control of MDM4 by p76
MDM2 reflects on p53 function as p76 MDM2 impairs MDM4-mediated inhibition of p53 activity. In agreement with the positive role of p76 MDM2 toward p53, the p76 MDM2 / p90 MDM2 ratio significantly decreases in a group of thyroid tumor samples compared with normal counterparts. Overall, these findings reveal a new mechanism in the control of p53 basal activity that may account for the distinct sensitivity of tissues to stress signals depending on the balance among MDM proteins. Moreover, these data suggest an oncosuppressive function for a product of the Mdm2 gene.
Introduction
The activation of the oncosuppressor p53 leads to different outcomes, all strongly affecting cell growth and viability. P53 basal activity is therefore strictly controlled to avoid unwarranted anomalies of cell growth. Moreover, levels of p53 basal activity control the magnitude of its stress-induced biological responses, including those raised by oncogenic stimuli . In normal growing cells, p53 is regulated in a non-redundant manner by MDM family members, MDM4 and MDM2 (Marine et al., 2006) . Although contribution of each of these proteins has not yet been completely resolved, their activity results in the control of p53 levels and function. An exception in the MDM group is represented by p76 MDM2 , an MDM2 protein that acts positively toward p53 (Perry et al., 2000) . P76
MDM2 derives from alternative translation of fulllength MDM2 mRNA. Indeed, MDM2, both human and mouse, gives rise to two major proteins starting from two different AUGs and differing in molecular weight, p90 MDM2 and p76 MDM2 (Saucedo et al., 1999; Cheng and Cohen, 2007) . P90 MDM2 , the more abundant form, binds p53 through its amino-terminus and controls both p53 protein levels, through its E3 ubiquitin ligase activity, as well as p53 transcriptional function (Marine and Lozano, 2010) . P76 MDM2 lacks the first N-terminal 49 amino acids, in which part of the p53-binding domain resides, and cannot bind p53. Nonetheless, it is able to affect p53 activity by stabilizing its protein levels and favoring its transcriptional function (Perry et al., 2000) . Thus far, p76 MDM2 function has been attributed to its ability to inhibit p90-degradative function, although neither association of p90 MDM2 with p53 nor total levels of p90 MDM2 result decreased by p76 MDM2 (Perry et al., 2000) . Despite the lack of a clear molecular function, in vivo data suggest that p76 MDM2 represents an important factor in the control of p53 activity. Indeed, p90 MDM2 is more abundant than p76 MDM2 in the brain, heart and kidney, whereas p76 MDM2 and p90 MDM2 are roughly equivalent in the spleen, thymus and intestine, tissues where p53 rapidly accumulate and is active in response to DNA damage (Perry et al., 2000) . In addition, a recent report has shown increased expression of p76 MDM2 associated with enhanced activity of p53 in the epidermal vitiligo lesions (Salem et al., 2009) , suggesting a function for p76 MDM2 in some pathological conditions too.
MDM family includes MDM4 (also known as MDMX) too. MDM4 is an inhibitor of p53 activity under normal growth conditions (Marine et al., 2006; Wang et al., 2009) , whereas it exerts a positive function toward p53-mediated apoptosis upon lethal DNA damage (Mancini and Moretti, 2009 ). Similar to p90 MDM2 , MDM4 inhibits p53 by controlling its protein levels and transcriptional function. However, MDM4 lacks E3 ubiquitin ligase activity and its ability to control p53 protein levels is mediated by heterodimerization with p90
MDM2
, which as a consequence acquires increased degradative potential toward p53 (Linares et al., 2003; Kawai et al., 2007; Linke et al., 2008; Okamoto et al., 2009) .
Although p76 MDM2 shares with p90 MDM2 the same protein domain at which levels MDM4 heterodimerizes, the function of p76 MDM2 toward MDM4 in the regulation of p53 has not been investigated.
In this work, we provide evidence that p76 MDM2 antagonizes MDM4 activity. In particular, we show that p76 MDM2 controls MDM4 protein levels by ubiquitinating and degrading it. Further, we showed that p76 MDM2 impairs the association of MDM4 with p90 MDM2 and p53, thereby reducing the degradative activity of the heterodimer toward p53. Most importantly, the ratio of p76 MDM2 to p90 MDM2 levels was significantly decreased in a group of human thyroid tumors compared with matched normal tissues, supporting the role of p76 MDM2 -positive activity toward p53.
Results

P76
MDM2 counteracts MDM4 activity on p53 independently of p90 MDM2 P76 MDM2 , which does not bind p53, acts positively on p53 activity (Perry et al., 2000; Cheng and Cohen, 2007) . P76 MDM2 activity has been related to its ability to antagonize the degradative function of p90
MDM2
. Its relationship with MDM4 has not been investigated.
Here, we tested the consequences of p76 MDM2 expression on MDM4-mediated inhibition of p53 transcriptional activity in Mdm2
MEFs (TKOMEFs). In agreement to that described previously, MDM4 inhibits p53 transactivating function, although less strongly than p90 MDM2 ( Figure 1a ). The expression of p76 MDM2 per se did not alter p53 activity; however, it partly prevented MDM4-mediated inhibition of p53 activity, indicating its ability to antagonize MDM4 repression, independently of the presence of p90 MDM2 ( Figure 1a ). In accordance with Perry's work, p76 MDM2 antagonizes p90
MDM2 -mediated inhibition of p53 too (Perry et al., 2000) . Similar results were obtained in
MEFs (DKO-MEFs) (data not shown). Luciferase data were confirmed by quantitative real-time PCR (qRT-PCR) analysis of endogenous p21 and Noxa, two p53-induced targets in MEFs . MDM4 represses moderately p53 activation of p21 and Noxa and p76 MDM2 counteracts such repression (Figure 1b) .
The antagonism of p76 MDM2 toward p90 MDM2 has been attributed to the inhibition of p90 MDM2 -mediated degradation of p53. However, MDM4 does not possess degradative function. Indeed, p53 protein levels did not MDM2 activity toward MDM4, we analyzed whether the presence of the deubiquitinating enzyme HAUSP could antagonize MDM4 downregulation by p76 MDM2 . Indeed, co-expression of HAUSP counteracted p76 MDM2 -mediated degradation of MDM4, confirming the role of ubiquitination in MDM4 degradation ( Figure 2c ). In comparison, p90 MDM2 does not degrade MDM4 and co-expression of HAUSP does not alter MDM4 protein levels.
These data indicate that p76 MDM2 possesses intrinsic ubiquitination function and that through this activity controls MDM4 protein levels. MDM2 are present simultaneously in the cell, we analyzed whether p76
MDM2 activity results in cooperation with p90 MDM2 . To this aim, the effects of p76 MDM2 toward MDM4 with respect to p90 MDM2 or in combination with it were compared. As reported previously, expression of p76 MDM2 in DKO-MEFs strongly decreased MDM4 protein levels ( Figure 3a ). In comparison, expression of p90 MDM2 did not do so. Co-expression of p90 MDM2 and p76 MDM2 did not lead to a further decrease of MDM4 levels, rather to an increase, indicating that the two MDM2 proteins do not synergize in controlling MDM4 amount. In comparison with full-length protein, levels of the MDM4 carboxy-terminus truncated form, p54
MDM4 (Gentiletti et al., 2002) , were not altered by p76 MDM2 or p90 MDM2 ( Figure 3a ). As p54 MDM4 lacks the RING finger domain through which MDM4 interacts with the MDM2 proteins, these data indicate the requirement of the association between MDM4 and p76 MDM2 for the activity of this last. Similar results were obtained in TKO-MEFs (data not shown).
These data indicate that p76 MDM2 controls MDM4 independently of p90 MDM2 and more efficiently. Furthermore, they suggest that the presence of p90
antagonizes rather than cooperates with p76 MDM2 . Accordingly, binding of p76 MDM2 and p90 MDM2 to MDM4 was mutually exclusive as increased amounts of p76 MDM2 lead to a decrease of p90 MDM2 associated with MDM4 ( Figure 3b) . In agreement to that described previously, the 3 0 -tagged MDM4-HA was resistant to degradation (Pan and Chen, 2003) .
Recent reports hypothesize that the association between MDM4 and p90 MDM2 stabilizes their complex and that heterodimer MDM4/p90
MDM2 is the prevalent -mediated degradation of p53 is owing to the displacement of MDM4 from the complex.
P76
MDM2 controls cytoplasmic MDM4 basal levels Given the ability of p76 MDM2 to affect MDM4 but not p90
MDM2
, and the inefficacy of p90 MDM2 toward MDM4, we asked whether p76 MDM2 function may be mediated by a different localization with respect to p90 MDM2 . We analyzed nuclear and cytoplasmic fractions of DKOMEFs expressing MDM4, p76 
P90
MDM2 is present in both nuclear and cytoplasmic compartments similar to p76 MDM2 (Figure 4a ). MDM4 localizes almost exclusively in the cytoplasm (Migliorini et al., 2002; Mancini et al., 2009b) and its localization is not modified by the presence of p76 MDM2 or p90
MDM2
. As observed previously, its levels are decreased upon coexpression with p76
MDM2 , but not with p90 MDM2 (Figure 4a) , and recovered by MG132 treatment (Figure 4b ). These data indicate that p76 MDM2 does not substantially change MDM4 intracellular localization and that its activity occurs in the cytoplasm. They further exclude that the inefficacy of p90 MDM2 is owing to a different localization.
At this point, we ascertained whether endogenous p76 MDM2 actually controls MDM4 levels. To this purpose, we interfered with p76 MDM2 expression by small interfering RNA (siRNA) in MCF10A, a non-transformed cell line, and analyzed MDM4 protein levels. Given the common mRNA, siRNA targeted both p76 MDM2 and p90
. The decrease of p76 MDM2 , as specifically detected by comparison of 2A10 antibody signal (able to detect p76 MDM2 ) with that of 4B2 (unable to detect p76 MDM2 ), correlated with a strong increase of MDM4 protein levels (Figure 4c ). This increase was reduced in the presence of MG132, confirming that the modulation occurs at protein levels. The siRNA reduced the levels of p90 MDM2 as well; however, on the basis of previous and published data , we exclude a relevant activity of p90 MDM2 . Interestingly, p53 protein levels result in an increase, as expected from the downregulation of p90
, but this did not result in a detectable increase of its targets p21 or Bax, suggesting that its transcriptional function is impaired in agreement with the simultaneous increase of MDM4 levels.
Overall, these data confirm that p76 MDM2 is an important factor in the positive control of p53 activity through the regulation of MDM4. -positive activity towards p53, we wondered whether p76 MDM2 levels are altered in human tumors. To this aim, a set of human thyroid tumor samples characterized by wt-p53 were compared with matched normal thyroid tissues (Prodosmo et al., 2008) . Although p76 MDM2 and p90
share the same mRNA, transcription initiated at the promoter P1 of human MDM2 has the ability to generate both MDM2 protein isoforms, whereas transcription initiated at the promoter P2 produces preferentially full-length p90 MDM2 (Cheng and Cohen, 2007) . As P1-driven transcript lacks exon 2, whereas P2-driven transcript lacks exon 1 (Cheng and Cohen, 2007) , P1 and P2 transcripts were analyzed by appropriate primers sets and P1/P2 ratio calculated in tumor samples compared with normal tissues. Interestingly, a significant decrease of P1/P2 ratio was observed in thyroid tumors compared with normal thyroid tissues ( Figure 5) MDM2 were grown in the absence or presence of adriamycin (Adr) for 8 h and then analyzed for MDM4 protein levels.
In the absence of Adr, MDM4 levels were strongly reduced by the presence of p76 MDM2 but not of p90 MDM2 , confirming previous results (Figure 6a ). Conversely, in the presence of Adr, p76 MDM2 did not reduce to a similar extent MDM4 levels (Figure 6a , lanes 7 and 5), whereas p90 MDM2 did it efficiently (Figure 6a , lanes 6 and 5). Co-expression of the two proteins did not synergize in MDM4 degradation, similar to that observed previously (see Figure 3a) . These data indicate that p76 MDM2 is ineffective in the control of MDM4 upon DNA damage and suggest a distinct control of MDM4 by p76 MDM2 and p90
, depending upon cell growth conditions.
The inefficacy of p90 MDM2 to control MDM4 under normal growth conditions is correlated with its association to HAUSP that counteracts p90 MDM2 -mediated degradation . We therefore asked whether the switch of MDM4 degradation from p76 MDM2 to p90 MDM2 is owing to a different association of HAUSP with these proteins. However, the complexes between HAUSP and MDM4 are not substantially altered in the presence of p76 MDM2 or p90 MDM2 , nor any difference was found in the association HAUSP/p76 MDM2 or HAUSP/p90 MDM2 (Figure 6b ), suggesting that HAUSP is not a determinant factor in the switch of MDM4 degradation between p76 MDM2 and p90 MDM2 . To further understand the molecular mechanism that controls this switch, we analyzed the fraction of p76 MDM2 and p90 MDM2 bound to MDM4. NIH3T3 cells that endogenously express detectable levels of p76 MDM2 and p90 MDM2 (Perry et al., 2000) and stably express a doxycycline-inducible MDM4 (NIH3T3-MDM4) were used (Gentiletti et al., 2002) . During Adr treatment, p90 MDM2 levels were strongly upregulated, whereas those of p76 MDM2 increased to a lesser extent (Figure 6c , right panel), in accordance with Saucedo's work (1999) . Upon immunoprecipitation of cytoplasmic MDM4, a change in the proportion of the two MDM2 proteins associated with MDM4 occurred. In the absence of Adr, MDM4 is bound to p76 MDM2 more abundantly than to p90 MDM2 , whereas in the presence of Adr, the levels of p76 MDM2 bound to MDM4 decreased (Figure 6c, left panel) . At the latest time point, 16 h, an increase of the p76 MDM2 levels bound to MDM4 was detected again. These observations suggest that the different regulation of MDM4 by p76 MDM2 is associated with a change in their association. On the contrary, under the same conditions, the fraction of MDM4 associated with p90 MDM2 does not substantially change. Upon DNA damage, phosphorylation of MDM4 at specific residues occurs. As S403 residue is an important phosphorylation site (Chen et al., 2005; Pereg et al., 2005) , its role in the association of p76 MDM2 to MDM4 was investigated. Under non-stress conditions, p76 MDM2 co-immunoprecipitates wt-MDM4 and mutant MDM4S403A in a similar way (Figure 7a) . Conversely, following Adr treatment, immunoprecipitation of p76 MDM2 was able to co-immunoprecipitate MDM4S403A more efficiently than wt-MDM4 (Figure 7a ). The reciprocal co-immunoprecipitation confirmed these data (data not shown), indicating that phosphorylation of MDM4 at S403 have an important role in the dissociation of MDM4 from p76
. To confirm these data, we tested the ability of p76 MDM2 to degrade MDM4S403A upon DNA damage. Indeed, MDM4S403A levels were decreased by p76 MDM2 independently of cell growth conditions, whereas in comparison wt-MDM4 levels were decreased only in the absence of stress (Figure 7b ). As control, p90 MDM2 degrades wt-MDM4 only in the presence of Adr, whereas loses its activity towards MDM4S403A, as reported previously (Chen et al., 2005; Pereg et al., 2005) .
Overall, these results indicate that phosphorylation of MDM4 at Ser403 is an important factor in mediating p76 MDM2 activity toward MDM4 by controlling their association, and confirm that p76 MDM2 is a relevant regulator of basal levels of MDM4.
Discussion
Under normal growth conditions, p53 activity is tightly controlled by MDM family members, MDM2 and MDM4, and their derivative forms (Marine et al., 2006; Toledo and Wahl 2007; Mancini et al., 2009a) . All MDM members exert a negative function toward p53, by controlling its transcriptional function and/or protein levels. An exception is represented by p76 MDM2 , a protein deriving from translation of an internal AUG of the MDM2 full-length mRNA. For this reason, p76 MDM2 lacks the first 49 amino acids and is unable to bind p53. Despite this property, p76 MDM2 acts positively on p53 and its presence has been associated to increased p53 activity in both normal tissues (Perry et al., 2000) and human pathological conditions (Salem et al., 2009) , suggesting a potential role for this factor in the upregulation of p53 function.
Thus far, the molecular mechanism that underlies p76 MDM2 function has been ascribed to the antagonism toward its full-length partner, p90
MDM2
, particularly toward the degradative activity of this. However, this antagonism remains to be elucidated since p76 MDM2 does MDM2 regulates p53 through control of MDM4 S Giglio et al not squelch p90
MDM2 out from association with p53, nor decreases p90 MDM2 levels. Present data provide new molecular insights into p76 MDM2 activity. Indeed, we showed that p76 MDM2 exerts a tight control toward the other member of MDM family, MDM4. In particular, p76 MDM2 regulates MDM4 protein levels and impairs its association with p53/p90 MDM2 complex. This ultimately results in decreased p53 degradation and an increase of its transcriptional function.
In normal growing cells, control of p53 protein levels resides almost exclusively in the ubiquitin ligase p90 MDM2 . The association of MDM4 with p90 MDM2 is considered an important event in directing the p90 MDM2 activity specifically toward p53, pointing to the heterodimer MDM4/p90 MDM2 as the main controller of p53 levels under normal growth conditions (Kawai et al., 2007) . The ability of p76 MDM2 to decrease both MDM4 levels and its association with the p53/p90 MDM2 complex leads ultimately to imbalance in the function of the heterodimer and consequently to a decrease of p53 degradation (Figure 8 ).
Our data also show that p76
-mediated control of MDM4 levels contributes to increase the levels of transcriptional active p53, independently of the presence of p90 MDM2 . MDM4-mediated inhibition of p53 activity has been attributed both to the masking of p53 transactivation domain (Shvarts et al., 1996) and to the subtraction of p53 out of the nucleus (Ohtsubo et al., 2009 following DNA damage. A reason for this switch may reside in the need of controlling MDM4 in different cell compartments. In fact, although MDM4 is mainly a cytoplasmic protein, after DNA damage a fraction of it translocates into the nucleus (Li et al., 2002; LeBron et al., 2006; Wang et al., 2007) , in which endogenous p90 MDM2 is more abundant. Overall, the consequences of p76 MDM2 -mediated regulation of MDM4 are the attenuation of MDM4 and MDM2 inhibitory activity toward p53, pointing to p76 MDM2 as an important factor in the positive control of p53 function. In agreement with this hypothesis, analysis of mRNAs originating from MDM2 P1 and P2 promoters and giving rise to p76 MDM2 þ p90 MDM2 or only p90 MDM2 , respectively, showed a significant decrease of p90 þ p76/p90 ratio in a group of human papillary thyroid tumors compared with their matched normal tissues. P2 is a p53-sensitive promoter; however, different reports have evidenced its activation by transcription factors other than p53 (Dimitriadi et al., 2008; Pikkarainen et al., 2009; Zhou et al., 2009 ). MDM2 leads to p53 activation by both decreasing MDM4 protein levels and squelching MDM4 out of the MDM4/p90 MDM2 /p53 complex.
p76
MDM2 regulates p53 through control of MDM4 S Giglio et al Interestingly, increased activity of the P2 promoter has been associated with enhanced resistance to cell stress (Pikkarainen et al., 2009; Zhou et al., 2009) . Furthermore, analysis of MDM2 proteins in human tumors has evidenced the low frequency of p76 MDM2 expression in comparison with other MDM2 forms, supporting the hypothesis that its presence may not be beneficial for the oncogenic process (Bueso-Ramos et al., 1996; Ralhan et al., 2000) .
Conversely, the presence of p76 MDM2 has been observed in human vitiligo lesion samples associated with an increased transcriptional function of p53, particularly the growth arrest function (Salem et al., 2009) . We recently reported that cytoplasmic MDM4 facilitates p53 mitochondrial apoptosis (Mancini et al., 2009b) . The downregulation of MDM4 levels by p76 MDM2 in the cytoplasm may therefore also contribute to decrease p53 apoptotic potential, directing its function toward the growth arrest response as observed in the vitiligo samples.
Our data may also concur to explain an unresolved issue in the function of p53 in Mdm2 knockout mice . In this model, the absence of MDM2 leads to increased p53 levels, but the transcriptional activity of p53, normalized to protein amount, does not increase, suggesting that the upregulation of transcriptional inhibitors parallels the increase of p53 levels. On the basis of our data, it may now be inferred that the absence of p76 MDM2 in the knockout mice leads to increased MDM4 levels and therefore to decreased p53 transcriptional function.
Finally, our data indicate that p76 MDM2 is endowed of intrinsic properties of ubiquitin ligase and degradation highlighting the potential existence of specific and/or more affine targets of this minor form of MDM2 in comparison with the classical p90 MDM2 . In conclusion, our data highlight a complex interplay among MDM family members and their relationship in the fine regulation of p53 function. They further suggest that knowledge of their reciprocal expression pattern may be a more precise predictor of their alteration in human tumors.
Materials and methods
Cell culture, plasmids and transfections NIH3T3 mouse fibroblasts stably expressing MDM4 (A1-18 clone) were cultured according to Gentiletti et al. (2002) . Mdm4
À/À MEFs (kindly provided by Dr JC Marine), derived from the triple knockout mice, were cultured in Dulbecco's modified Eagle's medium high glucose plus 10% fetal bovine serum (Cambrex, Charles City, IA, USA). All experiments were performed between passages 4 and 10.
The EcoRI/HindIII fragment of cDNA encoding p76 MDM2 and MDM4 were used. Luciferase activity was assayed at 24 h on whole-cell extracts (Promega, Italia, Milano, Italy).
Immunoprecipitations and western blot analyses Cells were lysed in Saimod buffer (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 150 mM NaCl, 0.5% Triton X-100). Immunoprecipitations and nuclear and cytoplasmic fractions were performed as described previously (Mancini et al., 2009b) .
The following primary antibodies were used: rabbit anti-MDM4 polyclonal antibody R1 (against full-length human MDM4), mouse anti-MDM4 monoclonal antibody MDMX-82 (Sigma-Aldrich, St Louis, MO, USA), mouse anti-MDM2 monoclonal antibodies 2A10, 4B2, Ab1 (Calbiochem, San Diego, CA, USA), sheep anti-p53 polyclonal antibody Ab7 (Oncogene, San Diego, CA, USA), rabbit anti-USP7 polyclonal antibody (34A for western blot, 33A for immunoprecipitation-Bethyl Lab, Montgomery, TX, USA), mouse anti-p21 F5 and mouse anti-HA monoclonal antibodies, rabbit anti-Bax N-20 and rabbit anti-Sp1 sc-59 polyclonal antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse antitubulin monoclonal antibody (Sigma, St Louis, MO, USA) and rabbit anti-GFP polyclonal antibody (Invitrogen).
Small interfering RNA MDM2 and control siRNAs were generated by Dharmacon (Thermo Fisher Scientific, Lafayette, CO, USA). Target sequence of MDM2 mRNA is AACCACCTCACAGATTCCAGC and control scramble sequence is AAGCTTTTGTCATGGAGAACG. Cells were transfected using RNAiMAX reagent (Invitrogen).
Tissue samples and patients Twenty-eight papillary thyroid carcinomas and 28 matched normal thyroid tissue samples from the contralateral lobe from 28 patients were studied. All specimens were obtained from patients undergoing surgery at the University of Perugia from 1997 to 2007. Before the surgical procedure, all patients signed informed consent forms for collection of fresh thyroid samples for genetic studies. All specimens were sampled from the primary tumour at the time of surgery, snap-frozen and stored at À80 1C until use. Tumours containing at least 70% of tumour cells based on the ematoxylin/eosin staining were selected. All normal thyroid tissue from the contralateral lobe were histopathologically analysed for the presence of tumour.
qRT-PCR qRT-PCR was performed according to Prodosmo et al. (2008) . The analysis of P1 and P2 transcripts and mouse p21 and Noxa was driven by qRT-PCR using specific probes and SYBR Master mix (Applied Biosystems, Life Technologies Corporation, Carlsbad, CA, USA) with evaluation of dissociation curves (see Supplementary Table 1 for primers). Our results are expressed as relative units (RU) of target mRNA, referred to a sample called calibrator, chosen to represent 1 Â expression of the target gene. The calibrator used was the lowest value in the tissue collection under study. All samples express n-fold mRNA relative to the calibrator. Each tissue sample mRNA was normalized relative to p76 MDM2 regulates p53 through control of MDM4 S Giglio et al the GAPDH mRNA, and samples for p21 and Noxa were normalized relative to TBP mRNA. Statistical analysis was carried out using the Analyse-it software for Microsoft Excel (Analyse-it Software Ltd, Leeds, UK).
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